Vir Biotechnology, INC Form 4 insider transactions

Vir Biotechnology, Inc. Director Norbert Bischofberger has acquired 8,000 restricted stock units and 16,000 stock options, which are set to vest in May 2026.

Marianne De Backer, CEO of Vir Biotechnology, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold 7,373 shares of common stock on February 26, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director George A. Scangos sold 10,056 shares of Vir Biotechnology stock on February 24, 2025, to cover tax obligations related to vesting restricted stock units.

Ann M. Hanly, EVP & Chief Technology Officer of Vir Biotechnology, sold shares to cover tax obligations related to vesting restricted stock units.

EVP and Chief Financial Officer of Vir Biotechnology, Jason O'Byrne, reports the acquisition of restricted stock units and stock options.

Mark Eisner, EVP and Chief Medical Officer of Vir Biotechnology, acquired 40,000 shares of common stock and granted a power of attorney for SEC filings.

Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, acquired shares and options while selling shares to cover tax obligations related to vesting restricted stock units.

Marianne De Backer, CEO of Vir Biotechnology, acquired shares and options while selling shares to cover tax obligations related to vesting restricted stock units.

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, reports acquisition and disposal of company stock and stock options.

Director George A. Scangos sold shares of Vir Biotechnology to cover tax withholding obligations related to vesting restricted stock units.

Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 1,562 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Vicki L Sato, a director at Vir Biotechnology, sold 10,960 shares of common stock at $12.52 per share on January 8, 2025, under a pre-arranged 10b5-1 trading plan.

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold 76 shares of common stock acquired through the company's employee stock purchase program.

Vir Biotechnology's Chief Financial Officer, Jason O'Byrne, acquired 75,000 shares of common stock and 150,000 stock options on November 15, 2024.

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold 4,397 shares of common stock at a price of $10.11 on November 6, 2024, according to a Form 4 filing.

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold shares to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

George A. Scangos, a director at Vir Biotechnology, reported transferring shares of common stock for tax planning purposes.

Director Janet Napolitano of Vir Biotechnology sold 12,190 shares of common stock on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mark Eisner, EVP and Chief Medical Officer of Vir Biotechnology, acquired 75,000 shares of common stock and options to purchase 150,000 shares on July 15, 2024.

Marianne De Backer, CEO of Vir Biotechnology, reports a transfer of common stock for tax planning purposes, with no change in overall beneficial ownership.

Director Saira Ramasastry sold 4,000 shares of Vir Biotechnology (VIR) common stock at a price of $10.9473 on June 11, 2024.

Director Charles Elliott Sigal reports acquisition of shares and stock options in Vir Biotechnology, along with disposal of shares.

Director George A. Scangos reports acquisition of Vir Biotechnology shares and options, along with adjustments to beneficial ownership.

Director Vicki L Sato reported acquiring 8,000 shares of common stock and 16,000 stock options in Vir Biotechnology, Inc.

Director Saira Ramasastry reports acquisition of shares and stock options in Vir Biotechnology.

Director Robert Nelsen reported the acquisition of 8,000 common stock shares and a grant of 16,000 stock options in Vir Biotechnology, Inc.

Director Janet Napolitano reports acquisition of Vir Biotechnology shares and stock options.

Director Robert J. More reports acquisition of Vir Biotechnology shares and stock options, along with a disposition of shares, in a recent SEC filing.

Director Jeffrey S. Hatfield reports acquisition of Vir Biotechnology stock and options, signaling potential confidence in the company's future.